Domača stranEBS • NYSE
add
Emergent BioSolutions
Prejšnji trg. dan.
6,59 $
Dnevni razpon
6,19 $ - 6,47 $
Letni razpon
4,02 $ - 15,10 $
Tržna kapitalizacija
339,24 mio. USD
Povprečni obseg
1,26 mio.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NYSE
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | mar. 2025info | Sprememba L/L |
|---|---|---|
Prihodek | 222,20 mio. | −26,03 % |
Stroški poslovanja | 69,00 mio. | −31,68 % |
Čisti dohodek | 68,00 mio. | 655,56 % |
Čista dobičkovnost prihodkov | 30,60 | 920,00 % |
Earnings per share | 0,71 | 20,34 % |
EBITDA | 75,20 mio. | 12,57 % |
Efektivna davčna stopnja | 26,64 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | mar. 2025info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 149,10 mio. | 89,94 % |
Skupna sredstva | 1,43 mrd. | −20,93 % |
Skupne obveznosti | 873,40 mio. | −23,37 % |
Celoten lastniški kapital | 552,70 mio. | — |
Shares outstanding | 54,28 mio. | — |
Razmerje P/B | 0,65 | — |
Donosnost sredstev | 8,95 % | — |
Donosnost kapitala | 10,57 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | mar. 2025info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 68,00 mio. | 655,56 % |
Denar iz dejavnosti | −11,20 mio. | 82,11 % |
Denar iz naložb | 59,50 mio. | 650,93 % |
Denar iz financiranja | −400,00 tis. | −100,98 % |
Neto sprememba denarnih sredstev | 47,20 mio. | 244,34 % |
Prost denarni tok | −30,29 mio. | 51,86 % |
Vizitka
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
Generalni direktor
Datum ustanovitve
5. sep. 1998
Sedež organizacije
Spletno mesto
Zaposleni
900
